Ranibizumab for Macular Edema Due to Retinal Vein Occlusions: Implication of VEGF as a Critical Stimulator
Top Cited Papers
Open Access
- 1 April 2008
- journal article
- research article
- Published by Elsevier BV in Molecular Therapy
- Vol. 16 (4), 791-799
- https://doi.org/10.1038/mt.2008.10
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Clinical, Anatomic, and Electrophysiologic Evaluation Following Intravitreal Bevacizumab for Macular Edema in Retinal Vein OcclusionAmerican Journal of Ophthalmology, 2007
- INTRAVITREAL BEVACIZUMAB (AVASTIN) IN THE TREATMENT OF MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSIONRetina, 2007
- Interventions for Central Retinal Vein Occlusion: An Evidence-Based Systematic ReviewOphthalmology, 2007
- INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR CENTRAL AND HEMICENTRAL RETINAL VEIN OCCLUSIONSRetina, 2007
- Ranibizumab versus Verteporfin for Neovascular Age-Related Macular DegenerationThe New England Journal of Medicine, 2006
- Ranibizumab for Neovascular Age-Related Macular DegenerationThe New England Journal of Medicine, 2006
- DEVELOPMENT OF RANIBIZUMAB, AN ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR ANTIGEN BINDING FRAGMENT, AS THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATIONRetina, 2006
- INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT OF MACULAR EDEMA IN CENTRAL RETINAL VEIN OCCLUSIONRetina, 2006
- Intravitreal Sustained Release of VEGF Causes Retinal Neovascularization in Rabbits and Breakdown of the Blood– Retinal Barrier in Rabbits and PrimatesExperimental Eye Research, 1997
- Natural History and Clinical Management of Central Retinal Vein OcclusionAmerican Journal of Ophthalmology, 1997